Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: a population-based time series analysis

Original research
by
Garg, Ria et al

Release Date

2022

Geography

Canada

Language of Resource

English

Full Text Available

Yes

Open Access / OK to Reproduce

No

Peer Reviewed

Yes

Objective

We assessed the impact of COVID-19, which includes the declaration of a state of emergency and subsequent release of pandemic-specific OAT guidance on the prevalence of OAT discontinuation.

Findings/Key points

Following COVID-19, there was no significant change in the percentage of Ontarians who discontinued OAT, regardless of whether they were stabilized on treatment. However, mortality following OAT discontinuation must be noted, as approximately 1.4% and 0.8% of people who discontinued methadone and buprenorphine/naloxone respectively, died within 30 days of discontinuation.

Design/methods

Population-based time series analysis

Keywords

Transitions in care/treatment
Mortality
Substitution
About PWUD
Outcomes